Breaking News

In Big Win For 340B Hospitals, CMS Will Reverse Massive Drug Reimbursement Cut for 2023 and Seeks Input on Potential Remedies for Prior Years

340B provider groups strongly criticized the Centers for Medicare & Medicaid Services’ draft guidance for Medicare drug price negotiations.

The U.S. Centers for Medicare and Medicaid Services “fully anticipate[s]” applying a Medicare Part B reimbursement rate next year of average sales price ASP plus 6% to drugs and biologicals purchased through the 340B program, CMS announced late this afternoon.

Read More »

House GOP Task Force Apparently Takes a Pass on Making 340B Recommendations

Rep. Kevin Hern (R-OK) seated
A House GOP task force subcommittee chaired by Rep. Kevin Hern (R-Okla.) apparently has decided not to recommend 340B policies the party can advance if its takes control of the House following the November elections.

A U.S. House Republican task force assigned to develop proposals the party can advance if the GOP takes the majority in the November elections apparently chose not to make recommendations for the 340B program.

The Healthy Future Task Force’s affordability

Read More »

Feds Ask Appeals Court to Uphold HRSA’s 340B Program Violation Letters to Novo Nordisk and Sanofi

Seal of the U.S. Court of Appeals for the Third Circuit
The federal government wants the U.S. Third Circuit Court of Appeals to partially uphold and partially overturn a lower court's opinion in Novo Nordisk and Sanofi's consolidated 340B contract pharmacy cases.

A federal district judge was right to rule last November that drug makers Novo Nordisk and Sanofi may not tie strings to 340B pricing when providers use contract pharmacies, the federal government told a federal appeals court in Philadelphia last

Read More »

HHS Warns Pharmacies Not to Turn Away Women Requesting Abortion Medication

U.S. Dept. of Health and Human Services Office for Civil RIghts Guidance to Nation's Retail Pharmacies title page
HHS issued guidance to retail pharmacies about their legal duty to fill prescriptions for drugs that can end or prevent pregnancy.

The U.S. Department of Health and Human Services issued guidance to retail pharmacies yesterday about their “unique role … in ensuring access to comprehensive reproductive health care services”—including filling prescriptions for drugs that can end or prevent pregnancy.

Mifepristone and

Read More »

Merck Becomes Eighth Drug Maker to Sue HRSA in Defense of 340B Contract Pharmacy Restrictions

Merck flag with flag of the United States of America
Merck is the eighth drug manufacturer to sue HRSA in defense of conditions on 340B pricing when covered entities use contract pharmacies.

Drug manufacturer Merck sued the federal government on Friday over the government’s May 6 letter telling the company its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal. The government warned Merck it could be

Read More »

PhRMA and J&J File Amicus Briefs in Support of Novartis and United Therapeutics

U.S. District Judge Dabney Friedrich seated at a hearing
PhRMA and Johnson & Johnson filed briefs backing Novartis and United Therapeutics's appeals of U.S. District Judge Dabney Friedrich’s ruling in their 340B contract pharmacy lawsuits.

Pharmaceutical Research and Manufacturers of America and drug maker Johnson & Johnson each filed a friend of the court brief in June backing Novartis and United Therapeutics in those two companies’ appeals of a federal district judge’s November decision that

Read More »

Senate Democratic Drug Pricing Bill Buoyed by Large Savings Estimate

Congressional Budget Office logo
Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by 2021—a 19% annual increase—according to preliminary Congressional Budget Office estimates released this week.

U.S. Senate Democrats’ revamped drug pricing legislation would lower the federal deficit by $287 billion over 10 years, the nonpartisan Congressional Budget Office said late last week.

Last November, CBO estimated that drug pricing language in the House-passed Build Back

Read More »

340B Hospital Annual Recertification Begins Aug. 27

A red Certified stamp
Annual recertification of 340B eligibility for hospitals starts Aug. 24 and ends Sept. 19.

Hospitals enrolled in the 340B program will have to recertify their eligibility for reduced 340B drug pricing this year between Aug. 24 and Sept. 19, the U.S. Health Resources and Services Administration says.

340B covered entities must annually recertify their

Read More »

Analysts Still Digesting Senate Democratic Drug Pricing Bill’s 340B Changes

digital image of hand holding cash and hand holding pharmaceuticals
Covered entities are studying how a new drug pricing bill would affect access to 340B pricing on drugs subject to Medicare price negotiation.

If Congress votes to gives Medicare the power to negotiate some drug prices, drug manufacturers would not have to provide price concessions that exceed the lower of a drug’s 340B price or the Medicare negotiated price, according to a summary

Read More »

Hospital Groups Cite Supreme Court Decision in Latest Briefs Backing Feds in Lilly and AstraZeneca 340B Cases

digital image of a courtroom
Hospital groups urged two federal appeals court to back the government in its fight to force Lilly and AstraZeneca to end restrictions on 340B pricing when covered entities use contract pharmacies.

Five groups that represent 340B hospitals have filed briefs in two federal appeals courts backing the federal government in its fight to force drug manufacturers Eli Lilly and AstraZeneca to end restrictions on 340B drug discounts when covered entities use

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live